Inmune Bio (INMB) Net Cash Flow Growth (1y) (2019 - 2026)
Inmune Bio (INMB) Net Cash Flow Growth (1y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 172.72% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 53.21% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 47.11% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 75.60% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -100.75% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2,045.25% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -104.22% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 149.49% |
| 10 | Inmune Bio | 61.59 Mn | 43.18 Mn | - | -121.46% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -121.46% |
| Mar 31, 2026 | -119.55% |
| Dec 31, 2025 | 76.57% |
| Sep 30, 2025 | -299.36% |
| Jun 30, 2025 | 191.45% |
| Mar 31, 2025 | 84.46% |
| Dec 31, 2024 | -121.75% |
| Sep 30, 2024 | 165.81% |
| Jun 30, 2024 | 261.03% |
| Mar 31, 2024 | -774.32% |
| Dec 31, 2023 | -3.97% |
| Sep 30, 2023 | -26.64% |
| Jun 30, 2023 | 33.31% |
| Mar 31, 2023 | 85.98% |
| Dec 31, 2022 | 41.77% |
| Sep 30, 2022 | -107.48% |
| Jun 30, 2022 | -151.49% |
| Mar 31, 2022 | -134.81% |
| Dec 31, 2021 | -308.86% |
| Sep 30, 2021 | 130.37% |